Kobayashi Pharmaceutical Co., Ltd.

Equities

4967

JP3301100008

Personal Products

Delayed Japan Exchange 01:53:43 2024-07-25 am EDT 5-day change 1st Jan Change
5,892.00 JPY +4.28% Intraday chart for Kobayashi Pharmaceutical Co., Ltd. +4.89% -13.20%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Kobayashi Pharmaceutical Co., Ltd.(TSE:4967) dropped from S&P Japan Mid Cap 100 CI
Japan companies hog the spotlight as hedge funds tout their top Asia picks RE
A second Kobayashi Pharma Japan factory inspected over deaths RE
Kobayashi factory searched over deaths possibly linked to supplements RE
Kobayashi Pharmaceutical Recalls 'Beni-Koji' Supplement Following Report of Death, Kidney Damage MT
Tranche Update on Kobayashi Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 7, 2023. CI
Kobayashi Pharmaceutical Co., Ltd's Equity Buyback announced on November 7, 2023, has closed with 1,924,600 shares, for ¥11,999.88 million. CI
Kobayashi Pharmaceutical Co., Ltd. acquired Focus Consumer Healthcare, LLC. CI
Kobayashi Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Organ Technologies Inc announced that it has received funding from Kobayashi Pharmaceutical Co., Ltd. CI
Tranche Update on Kobayashi Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 1, 2022. CI
Kobayashi Pharmaceutical Co., Ltd.'s Equity Buyback announced on November 1, 2022, has closed with 1,150,602 shares, representing 1.49% for ¥9,991.92 million. CI
Kobayashi Pharmaceutical Co., Ltd. announces an Equity Buyback for 1,265,800 shares, representing 1.64% for ¥9,999.82 million. CI
Kobayashi Pharmaceutical Co., Ltd. authorizes a Buyback Plan. CI
Kobayashi Pharmaceutical Co., Ltd. Provides Earnings Guidance for the Full Year 2022 CI
UBS Adjusts Kobayashi Pharmaceutical's Price Target to 12,600 Yen From 13,100 Yen, Keeps at Buy MT
Tranche Update on Kobayashi Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on October 28, 2021. CI
Kobayashi Pharmaceutical Co., Ltd.'s Equity Buyback announced on October 28, 2021, has expired with 883,300 shares, representing 1.13% for ¥7,999.54 million. CI
Kobayashi Pharmaceutical Co., Ltd. announces an Equity Buyback for 1,000,000 shares, representing 1.28% for ?8,000 million. CI
Kobayashi Pharmaceutical Co., Ltd. authorizes a Buyback Plan. CI
Kobayashi Pharmaceutical Co., Ltd. acquired Alva-Amco Pharmacal Companies, Inc. from Trusts all owned by the founder's family for approximately $110 million. CI
Kobayashi Pharmaceutical Co., Ltd.(TSE:4967) added to S&P Japan Mid Cap 100 CI
Tranche Update on Kobayashi Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on January 31, 2019. CI
Kobayashi Pharmaceutical Co., Ltd.'s Equity Buyback announced on January 31, 2019 has expired with 909,500 shares for ¥7,999.28 million. CI
Kobayashi Pharmaceutical Co., Ltd. acquired Meitanhonpo.Co.,Ltd. CI
Chart Kobayashi Pharmaceutical Co., Ltd.
More charts
Logo Kobayashi Pharmaceutical Co., Ltd.
KOBAYASHI PHARMACEUTICAL CO., LTD. a drug manufacturer. The Company operates in three segments. The Domestic Household Products Manufacturing and Sales segment and Overseas Household Products Manufacturing and Sales segment offer health care, daily necessities, skin care and other products. The Mail Order segment involves in the mail order of dietary supplements, skin care products and others.
Employees
3,534
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
7
Last Close Price
5,650.00JPY
Average target price
5,941.43JPY
Spread / Average Target
+5.16%
Consensus
  1. Stock Market
  2. Equities
  3. 4967 Stock
  4. News Kobayashi Pharmaceutical Co., Ltd.
  5. UBS Adjusts Kobayashi Pharmaceutical's Price Target to 12,600 Yen From 13,100 Yen, Keeps at Buy